Literature DB >> 15294956

The 4-1BB costimulation augments the proliferation of CD4+CD25+ regulatory T cells.

Guoxing Zheng1, Bin Wang, Aoshuang Chen.   

Abstract

The thymus-derived CD4(+)CD25(+) T cells belong to a subset of regulatory T cells potentially capable of suppressing the proliferation of pathogenic effector T cells. Intriguingly, these suppressor cells are themselves anergic, proliferating poorly to mitogenic stimulation in culture. In this study, we find that the 4-1BB costimulator receptor, best known for promoting the proliferation and survival of CD8(+) T cells, also induces the proliferation of the CD4(+)CD25(+) regulatory T cells both in culture and in vivo. The proliferating CD4(+)CD25(+) T cells produce no detectable IL-2, suggesting that 4-1BB costimulation of these cells does not involve IL-2 production. The 4-1BB-expanded CD4(+)CD25(+) T cells are functional, as they remain suppressive to other T cells in coculture. These results support the notion that the peripheral expansion of the CD4(+)CD25(+) T cells is controlled in part by costimulation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15294956     DOI: 10.4049/jimmunol.173.4.2428

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  47 in total

1.  Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice.

Authors:  Liguo Niu; Simona Strahotin; Becker Hewes; Benyue Zhang; Yuanyuan Zhang; David Archer; Trent Spencer; Dirck Dillehay; Byoung Kwon; Lieping Chen; Anthony T Vella; Robert S Mittler
Journal:  J Immunol       Date:  2007-04-01       Impact factor: 5.422

2.  Involvement of 4-1BB (CD137)-4-1BBligand interaction in the modulation of CD4 T cell-mediated inflammatory colitis.

Authors:  P Maerten; B S Kwon; C Shen; G De Hertogh; P Cadot; D M A Bullens; L Overbergh; C Mathieu; G Van Assche; K Geboes; P Rutgeerts; J L Ceuppens
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

3.  Cutting edge: Immunosuppressant as adjuvant for tolerogenic immunization.

Authors:  Youmin Kang; Lipeng Xu; Bin Wang; Aoshuang Chen; Guoxing Zheng
Journal:  J Immunol       Date:  2008-04-15       Impact factor: 5.422

4.  CD137 costimulation of CD8+ T cells confers resistance to suppression by virus-induced regulatory T cells.

Authors:  Shelly J Robertson; Ronald J Messer; Aaron B Carmody; Robert S Mittler; Christopher Burlak; Kim J Hasenkrug
Journal:  J Immunol       Date:  2008-04-15       Impact factor: 5.422

5.  The CD137 Ligand Is Important for Type 1 Diabetes Development but Dispensable for the Homeostasis of Disease-Suppressive CD137+ FOXP3+ Regulatory CD4 T Cells.

Authors:  Bardees M Foda; Ashley E Ciecko; David V Serreze; William M Ridgway; Aron M Geurts; Yi-Guang Chen
Journal:  J Immunol       Date:  2020-04-15       Impact factor: 5.422

Review 6.  CD25+ CD4+ regulatory T-cells in cancer.

Authors:  David C Linehan; Peter S Goedegebuure
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 7.  Function of tumor necrosis factor receptor family members on regulatory T-cells.

Authors:  Robert H Arch
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

8.  The B10 Idd9.3 locus mediates accumulation of functionally superior CD137(+) regulatory T cells in the nonobese diabetic type 1 diabetes model.

Authors:  Kritika Kachapati; David E Adams; Yuehong Wu; Charles A Steward; Daniel B Rainbow; Linda S Wicker; Robert S Mittler; William M Ridgway
Journal:  J Immunol       Date:  2012-10-12       Impact factor: 5.422

9.  A Combination of Systemic and Intracranial Anti-CD25 Immunotherapy Elicits a Long-Time Survival in Murine Model of Glioma.

Authors:  Marie-Denise Poirier; Houda Haban; Abdeljabar El Andaloussi
Journal:  J Oncol       Date:  2010-03-21       Impact factor: 4.375

10.  Adjuvantive effects of anti-4-1BB agonist Ab and 4-1BBL DNA for a HIV-1 Gag DNA vaccine: different effects on cellular and humoral immunity.

Authors:  Sumita Ganguly; Jinyan Liu; Vinod B Pillai; Robert S Mittler; Rama Rao Amara
Journal:  Vaccine       Date:  2009-11-26       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.